498 related articles for article (PubMed ID: 12391241)
41. Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatic renal cell carcinoma treated with dendritic cell vaccines.
Arroyo JC; Gabilondo F; Llorente L; Meraz-Ríos MA; Sánchez-Torres C
J Clin Immunol; 2004 Jan; 24(1):86-96. PubMed ID: 14997038
[TBL] [Abstract][Full Text] [Related]
42. Low molecular weight hyaluronan preconditioning of tumor-pulsed dendritic cells increases their migratory ability and induces immunity against murine colorectal carcinoma.
Alaniz L; Rizzo M; Garcia MG; Piccioni F; Aquino JB; Malvicini M; Atorrasagasti C; Bayo J; Echeverria I; Sarobe P; Mazzolini G
Cancer Immunol Immunother; 2011 Oct; 60(10):1383-95. PubMed ID: 21638126
[TBL] [Abstract][Full Text] [Related]
43. Specific targeting of whole lymphoma cells to dendritic cells ex vivo provides a potent antitumor vaccine.
Adam C; Mysliwietz J; Mocikat R
J Transl Med; 2007 Mar; 5():16. PubMed ID: 17359532
[TBL] [Abstract][Full Text] [Related]
44. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
[TBL] [Abstract][Full Text] [Related]
45. In vitro priming of myeloma antigen-specific allogeneic donor T cells with idiotype pulsed dendritic cells.
Kim SB; Baskar S; Kwak LW
Leuk Lymphoma; 2003 Jul; 44(7):1201-8. PubMed ID: 12916873
[TBL] [Abstract][Full Text] [Related]
46. Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma.
Wong CP; Levy R
Cancer Res; 2000 May; 60(10):2689-95. PubMed ID: 10825142
[TBL] [Abstract][Full Text] [Related]
47. Human autologous tumor-specific T-cell responses induced by liposomal delivery of a lymphoma antigen.
Neelapu SS; Baskar S; Gause BL; Kobrin CB; Watson TM; Frye AR; Pennington R; Harvey L; Jaffe ES; Robb RJ; Popescu MC; Kwak LW
Clin Cancer Res; 2004 Dec; 10(24):8309-17. PubMed ID: 15623607
[TBL] [Abstract][Full Text] [Related]
48. A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.
Chiang CL; Kandalaft LE; Tanyi J; Hagemann AR; Motz GT; Svoronos N; Montone K; Mantia-Smaldone GM; Smith L; Nisenbaum HL; Levine BL; Kalos M; Czerniecki BJ; Torigian DA; Powell DJ; Mick R; Coukos G
Clin Cancer Res; 2013 Sep; 19(17):4801-15. PubMed ID: 23838316
[TBL] [Abstract][Full Text] [Related]
49. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses.
Dashti A; Ebrahimi M; Hadjati J; Memarnejadian A; Moazzeni SM
Cancer Lett; 2016 Apr; 374(1):175-185. PubMed ID: 26803056
[TBL] [Abstract][Full Text] [Related]
50. Enhanced anti-tumor immunity by superantigen-pulsed dendritic cells.
Kato M; Nakamura Y; Suda T; Ozawa Y; Inui N; Seo N; Nagata T; Koide Y; Kalinski P; Nakamura H; Chida K
Cancer Immunol Immunother; 2011 Jul; 60(7):1029-38. PubMed ID: 21519830
[TBL] [Abstract][Full Text] [Related]
51. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein.
Shimizu K; Thomas EK; Giedlin M; Mulé JJ
Cancer Res; 2001 Mar; 61(6):2618-24. PubMed ID: 11289139
[TBL] [Abstract][Full Text] [Related]
52. Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.
Pyzer AR; Avigan DE; Rosenblatt J
Hum Vaccin Immunother; 2014; 10(11):3125-31. PubMed ID: 25625926
[TBL] [Abstract][Full Text] [Related]
53. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
Aravindaram K; Wang PH; Yin SY; Yang NS
Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
[TBL] [Abstract][Full Text] [Related]
54. Dendritic cell-based therapeutic vaccination against myeloma: vaccine formulation determines efficacy against light chain myeloma.
Cohen S; Haimovich J; Hollander N
J Immunol; 2009 Feb; 182(3):1667-73. PubMed ID: 19155516
[TBL] [Abstract][Full Text] [Related]
55. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
[TBL] [Abstract][Full Text] [Related]
56. B7-1, IFN gamma and anti-CTLA-4 co-operate to prevent T-cell tolerization during immunotherapy against a murine T-lymphoma.
Van Ginderachter JA; Liu Y; Geldhof AB; Brijs L; Thielemans K; De Baetselier P; Raes G
Int J Cancer; 2000 Aug; 87(4):539-47. PubMed ID: 10918195
[TBL] [Abstract][Full Text] [Related]
57. NKT and CD8 lymphocytes mediate suppression of hepatocellular carcinoma growth via tumor antigen-pulsed dendritic cells.
Shibolet O; Alper R; Zlotogarov L; Thalenfeld B; Engelhardt D; Rabbani E; Ilan Y
Int J Cancer; 2003 Aug; 106(2):236-43. PubMed ID: 12800200
[TBL] [Abstract][Full Text] [Related]
58. Innate NKT lymphocytes confer superior adaptive immunity via tumor-capturing dendritic cells.
Liu K; Idoyaga J; Charalambous A; Fujii S; Bonito A; Mordoh J; Wainstok R; Bai XF; Liu Y; Steinman RM
J Exp Med; 2005 Dec; 202(11):1507-16. PubMed ID: 16330814
[TBL] [Abstract][Full Text] [Related]
59. Intratumoral immunotherapy for melanoma.
Singh M; Overwijk WW
Cancer Immunol Immunother; 2015 Jul; 64(7):911-21. PubMed ID: 26050024
[TBL] [Abstract][Full Text] [Related]
60. Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine.
Kao JY; Gong Y; Chen CM; Zheng QD; Chen JJ
J Immunol; 2003 Apr; 170(7):3806-11. PubMed ID: 12646647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
